Comparative Pharmacology
Head-to-head clinical analysis: ELTROMBOPAG OLAMINE versus NPLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELTROMBOPAG OLAMINE versus NPLATE.
ELTROMBOPAG OLAMINE vs NPLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), leading to increased proliferation and differentiation of megakaryocytes and subsequent platelet production.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), stimulating megakaryocyte proliferation and differentiation, leading to increased platelet production.
50 mg orally once daily; for patients of East Asian ancestry with ITP, start at 25 mg orally once daily. Dose adjustments based on platelet counts: increase up to 75 mg daily or decrease to 25 mg daily as needed.
1 mcg/kg subcutaneously once weekly, based on actual body weight.
None Documented
None Documented
Terminal elimination half-life is approximately 21–32 hours (mean ~29 hours) in healthy subjects. At steady state, clinically relevant due to once-daily dosing with delayed platelet response.
Terminal half-life is 1–2 days (median 1.4 days) after weekly SC dosing; supports weekly administration.
Primarily fecal (59%) and renal (31%), with unchanged drug representing <1% in urine and ~20% in feces; biliary elimination accounts for most of the fecal route.
Renal excretion is minimal (<5% as unchanged drug); metabolism is expected via proteolysis to small peptides and amino acids; no biliary/fecal data available.
Category C
Category C
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist